Population correlates of coagulation factor VII: Importance of age, sex, and menopausal status as determinants of activated factor VII

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 16, Issue 9, 1996, Pages 1170-1176

  Scarabin, Pierre Yves ^a   Vissac, Anne Marie ^b   Kirzin, Jean Michel ^c   Bourgeat, Pierre ^b   Amiral, Jean ^b   Agher, Rachid ^a   Guize, Louis ^c  

^a HÔPITAL BROUSSAIS   (France)

^b Laboratoire Serbio   (France)

^c Ctr d'Investigations P   (France)

Author keywords

activated factor VII; factor VII antigen; factor VII coagulant activity; hormone replacement therapy; menopause

Indexed keywords

BLOOD CLOTTING FACTOR 7; CHOLESTEROL; ESTROGEN; ETHINYLESTRADIOL; GLUCOSE; LIPOPROTEIN A; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; TRIACYLGLYCEROL;

ADULT; AGING; ARTICLE; CORONARY ARTERY DISEASE; ESTROGEN THERAPY; FEMALE; HEART PROTECTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MENOPAUSE; ORAL CONTRACEPTION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE;

EID: 0029737825     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.16.9.1170     Document Type: Article

References (44)

1. Morrissey JH. Tissue factor interactions with factor VII: measurement and clinical significance of factor VIIa in plasma. Blood Coagul Fibrinolysis. 1995;6:S14-S19.
2. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North RR, Haines AP, Stirling Y, Imeson JD, Thompson SG. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet. 1986;2:533-537.
3. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet, 1993;342:1076-1079.
4. Heinrich J, Balleisen L, Schulte H, Assmann G, Van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk: results from the PROCAM Study in healthy men. Arterioscler Thromb. 1994;14:54-59.
5. Brozovic M, Stirling Y, Harricks C, North WRS, Meade TW. Factor VII in an industrial population. Br J Haematol. 1974;28:3SJ-391.
6. Balleisen L, Bailey J, Epping PH, Schulte H, Van de Loo J. Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population, I: baseline data on the relation to age, gender, body weight, smoking, alcohol, pill using and menopause. Thromb Haemost. 1985;54:475-479.
7. Scarabin PY, Van Dreden P, Bonithon-Kopp C, Orssaud G, Bara L, Conard J, Samama M. Age-related changes in factor VII activation in healthy women. Clin Sci. 1988;75:341-343.
8. Folsom AR, Wu KK, Davis CE, Conlan MG, Sorlie PD, Szklo M. Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors. Atherosclerosis. 1991;91:191-205.
9. Kario K, Matsuo T, Nakao K. Factor VII hyperactivity in the elderly. Thromb Haemost. 1991;65:25-27.
10. Meade TW, Imeson JD, Haines AP, Stirling Y, Thompson SG. Menopausal status and haemostatic variables. Lancet. 1986;1:22-24.
11. Scarabin PY, Bonithon-Kopp C, Bara L, Malmejac A, Guize L, Samama M. Factor VII activation and menopausal status. Thromb Res. 1990;57:227-234.
12. Brunner EJ, Marmot MG, White IR, O'Brien JR, Etherington MD, Slavin BM, Kearnet EM, Smith GD. Gender and employment grade differences in blood cholesterol apolipoproteins and haemostatic factors in the Whitehall II Study. Atherosclerosis. 1993;102:195-207.
13. Poller L, Thompson JM. Clotting factors during oral contraception: further report. Br Med J. 1992;2:23-25.
14. Meade TW, Haines AP, North WRS, Chakrabarti RR, Howarth DJ, Stirling Y. Haemostatic, lipid and blood pressure profiles of women on oral contraceptives containing 50μg and 30 μg oestrogen. Lancet. 1977;2:948-951.
15. Plu-Bureau G, Scarabin PY, Bara L, Malmejac A, Guize L, Samama M. Factor VII activation and oral contraceptives. Thromb Res. 1993;70:275-280.
16. Balleisen L, Assmann G, Bailey J, Epping PH, Schulte H, Van de Loo J. Epidemiological study on factor VII: baseline data on the relation to blood pressure, blood glucose, uric acid and lipid fractions. Thromb Haemost. 1985;54:721-723.
17. Miller GJ, Walter SJ, Stirling Y, Thompson SG, Esnouf MP, Meade TW. Assay of factor VII activity by two techniques: evidence for an increased conversion of VII to (α-VIIa in hyperlipidemia, with possible implications for ischaemic heart disease. Br J Haematol. 1985;59:249-258.
18. Scarabin PY, Bara L, Samama M, Orssaud G. Further evidence that activated factor VII is related to plasma lipids. Br J Haematol. 1985;61:186-187.
19. Carvalho de Sousa J, Soria C, Ayrault-Jarrier M, Pastier D, Bruckert E, Amiral J, Bereziat G, Caen JP. Association between coagulation factors VII and X with triglyceride rich lipoprotein. J Clin Pathol. 1988;41:940-944.
20. Hoffman CJ, Miller RH, Hultin MB. Correlation of factor VII activity and antigen with cholesterol and triglycerides in healthy young adults. Arterioscler Thromb. 1992;12:267-270.
21. Miller GJ, Martin JC, Webster J, Wilkes H, Miller NE, Wilkinson WH, Meade TW. Association between dietary fat intake and plasma factor VII coagulant activity: a predictor of cardiovascular mortality. Atherosclerosis. 1986;60:269-277.
22. Seligsohn U, Osterud B, Rapaport SI. Coupled amidolytic assay of factor VII: its use with clotting assay to determine the activity state of factor VII. Blood. 1978;52:978-988.
23. Osterud B. How to measure factor VII and factor VII activation. Haemostasis. 1983;13:161-168.
24. Poggio M, Tripodi A, Mariani G. Mannucci PM. Factor VII clotting assay: influence of different thromboplastins and factor VII-deficient plasmas. Thromb Haemost. 1991;65:160-164.
25. Kitchen S, Malia RG, Preston FE. A comparison of methods for the measurement of activated factor VII. Thromb Haemost. 1992;68:301-305.
26. Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood. 1993;81:734-744.
27. Boyer D, Wolf M, Rothschild C, Migaud M, Amiral J, Mannucci PM, Meyer D, Larrieu MJ. An enzyme immunoassay (Elisa) for the quantification for human factor VII. Thromb Haemost. 1986;56:250-255.
28. Mann KG. Factor VII assays, plasmas triglycerides levels, and cardiovascular disease risk. Arteriosclerosis. 1989;9:783-784.
29. Dalaker K, Skartlien AH, Prydz H. A new form of coagulation factor VII in plasma. Scand J Haematol. 1986;36:430-438.
30. Miller GJ, Stirling Y, Esnouf MP, Heinrich J, van de Loo J, Kienast J, Wu KK, Morrissey JH, Meade TW, Martin JC, Imeson JD, Cooper JA, Finch A. Factor Vil-deficient substrate plasmas depleted of protein C raise the sensitivity of the factor VII bio-assay to activated factor VII: an international study, Thromb Haemost. 1994;71:38-48.
31. Kario K, Miyata T, Sakata T, Matsuo T, Kalo H. Fluorogenic assay of activated factor VII: plasma factor Vila levels in relation to arterial cardiovascular diseases in Japanese. Arterioscler Thromb. 1994;14:265-274.
32. Kannel WB. Metabolic risk factors for coronary heart disease in women: perspective from the Framingham Study. Am Heart J. 1987;114:413-419.
33. Scarabin PY, Plu-Bureau G, Bara L, Bonithon-Kopp C, Guize L, Samama MM. Haemostatic variables and menopausal status: influence of hormone replacement therapy. Thromb Haemost. 1993;70:584-587.
34. Stampfer MJ, Willet WC, Colditz GA, Rosner B, Speizer FE, Hennekens CH. A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med. 1985;313:1044-1049.
35. Gebara OCE, Mittleman MA, Sutherland P, Lipinska I, Matheney T, Xu P, Welty FK, Wilson PWF, Levy D, Muller JE, Tofler GH. Association between increased estrogen status and increased fibrinolytic potential in the Framingham offspring study. Circulation. 1995;91:1952-1958.
36. Scarabin PY, Plu-Bureau G, Zitoun D, Bara L, Guize, Samama MM. Changes in haemostatic variables induced by oral contraceptives containing 50 μg or 30 μg of oestrogen: absence of dose-dependent effect on PAI-1 activity. Thromb Haemost. 1995;74:837-841.
37. Stolley PD, Strom BL, Sartwell PE. Oral contraceptives and vascular disease. Epidemiol Rev. 1989;11:241 -243.
38. Carvalho de Sousa J, Bruckert E, Giral P, Soria C, Chapman J, Truffert J, Dairou F, de Gennes JL, Caen JP. Coagulation factor VII and plasma triglycerides: decreased catabolism as a possible mechanism of factor VII hyperactivity. Haemostasis. 1989;19:125-130.
39. Moor M, Silveira A, van't Hoogt F, Suontaka AM, Eriksson P, Blombäck M, Hamsten A. Coagulation factor VII mass and activity in young men with myocardial infarction at a young age. Arterioscler Thromb Vase Biol. 1995;15:655-664.
40. Miller GJ, Martin JC, Mitropoulos KA, Reeves BEA, Thompson SG, Meade TW, Cooper JA, Cruickshank JK. Plasma factor VII is activated by postprandial triglyceridaemia, irrespective of dietary fat composition. Atherosclerosis. 1991;86:163-171.
41. Mitropoulos KA, Miller GJ, Watts GF, Durrington PN. Lipolysis of triglyccride-rich lipoproteins activates coagulant factor XII: a study in familial lipoprotein-Iipase deficiency. Atherosclerosis. 1992;95:119-125.
42. Mitropoulos KA, Miller GJ, Martin JC, Reeves BEA, Cooper J. Dietary fat induces changes in factor VII coagulant activity through effects on plasma free stearic acid concentration. Arterioscler Thromb. 1994;14:214-222.
43. Silveira A, Karpe F, Blomback M, Steiner G, Walldius G, Hamsten A. Activation of coagulation factor VII during alimentary lipemia, Arterioscler Thromb. 1994;14:60-69.
44. Merlini PA, Ardissino D, Oltrona L, Broccolino M, Coppola R, Mannucci PM. Heightened thrombin formation but normal plasma levels of activated factor VII in patients with acute coronary syndromes. Arterioscler Thromb Vase Biol. 1995;15:1675-1679.